Fri, January 24, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Wamsi Mohan Maintained (AAPL) at Buy with Decreased Target to $253 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Paul Lejuez Reinstated (ACI) to Buy and Held Target at $26 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Brett Fishbin Maintained (ALC) at Overweight with Decreased Target to $105 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
David Saxon Maintained (ALC) at Buy with Decreased Target to $106 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Gregory Renza Reiterated (AMGN) at Outperform and Held Target at $324 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Richard Hightower Maintained (AMH) at Equal with Decreased Target to $37 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
David George Maintained (ASB) at Neutral with Decreased Target to $26 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Karl Shepard Maintained (ASB) at Sector with Increased Target to $27 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Adam Kramer Downgraded (AVB) to Equal and Decreased Target to $223 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Richard Hightower Maintained (AVB) at Equal with Decreased Target to $230 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Jason Gursky Maintained (BA) at Buy with Decreased Target to $207 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Jared Shaw Maintained (BANC) at Overweight with Decreased Target to $19 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
David Williams Reiterated (BDC) at Buy and Held Target at $130 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Fawne Jiang Reiterated (BIDU) at Buy and Held Target at $130 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Joseph Greff Maintained (BYD) at Neutral with Increased Target to $80 on, Jan 24th, 2025
Thu, January 23, 2025
[ Thu, Jan 23rd 2025 ]: MSN
Avidity Biosciences CFO sells $93,985 in stock
[ Thu, Jan 23rd 2025 ]: MSN
2 'Strong Buy'-Rated Dividend Stocks With Yields Above 7% for 2025
[ Thu, Jan 23rd 2025 ]: MSN
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook
[ Thu, Jan 23rd 2025 ]: MSN
Diamondback Energy's SWOT analysis: stock poised for growth amid merger synergies
[ Thu, Jan 23rd 2025 ]: Forbes
S&P 500 Index Funds: Risks You Must Know Before You Invest
[ Thu, Jan 23rd 2025 ]: MSN
Are famous short-sellers going extinct? The exit .. nd Andrew Left shows the risky trade is shrinking
[ Thu, Jan 23rd 2025 ]: MSN
Is AbbVie Inc. (ABBV) the Best Halal Dividend Stock to Invest In Now?
[ Thu, Jan 23rd 2025 ]: MSN
Is Intel Corporation (INTC) One of the Best Socia .. sponsible Stocks to Buy According to Hedge Funds?
[ Thu, Jan 23rd 2025 ]: Forbes
Is Quantum Computing Investable As The Next AI
[ Thu, Jan 23rd 2025 ]: MSN
Is Johnson & Johnson (JNJ) the Best Halal Dividend Stock to Invest In Now?
[ Thu, Jan 23rd 2025 ]: MSN
BlackRock CEO Fink advocates for tokenization of stocks and bonds
[ Thu, Jan 23rd 2025 ]: MSN
Is PepsiCo, Inc. (PEP) the Best Halal Dividend Stock to Invest In Now?
[ Thu, Jan 23rd 2025 ]: AOL
Warren Buffett: 5 Stocks He's Dead Serious About In 2025
[ Thu, Jan 23rd 2025 ]: MSN
Is Medtronic plc (MDT) the Best Halal Dividend Stock to Invest In Now?
[ Thu, Jan 23rd 2025 ]: Forbes
What Are The Risks Of S&P 500 Index Funds?
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of EYPT at $8.86, after crossing above the $8.78 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of FMAO at $2 .. 7, after crossing above the $26.264 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of PLAY at $2 .. 4, after crossing above the $27.587 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of CHGCF at $ .. 2, after crossing above the $44.189 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of ACIC at $1 .. 2, after crossing above the $12.149 Trigger Price
[ Thu, Jan 23rd 2025 ]: MSN
How to Get Your Kids into Investing: A Family Project to Try
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of TENB at $4 .. 1, after crossing above the $42.514 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of UGI at $30 .. 9, after crossing above the $30.301 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of SD at $12.4, after crossing above the $12.372 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of PHG at $26 .. 2, after crossing above the $26.497 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of LVO at $1.25, after crossing above the $1.222 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of IVDN at $0 .. 32, after crossing above the $0.277 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of FMS at $24 .. 1, after crossing above the $23.655 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of BWB at $13 .. 5, after crossing above the $13.387 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of BUSE at $2 .. 4, after crossing above the $22.952 Trigger Price
[ Thu, Jan 23rd 2025 ]: MSN
Dave Ramsey: If You Invested $10K in These Companies, You'd Be Nearly $16K Richer
[ Thu, Jan 23rd 2025 ]: MSN
The Worst Mistakes Almost Every TFSA Holder Makes, and the CRA Is Watching
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of TXO at $19 .. 41, after crossing above the $19.19 Trigger Price

Altimmune's SWOT analysis: pemvidutide potential drives stock outlook

The article from MSN Money discusses Altimmune, Inc., a clinical-stage biopharmaceutical company, focusing on its SWOT analysis and the potential impact of its lead product candidate, pemvidutide, on its stock outlook. Pemvidutide is a GLP-1/glucagon dual receptor agonist aimed at treating obesity and non-alcoholic steatohepatitis (NASH). Strengths include a promising pipeline with pemvidutide showing significant weight loss in early trials, and a robust intellectual property portfolio. Weaknesses highlight the company's reliance on the success of pemvidutide, with no other products currently generating revenue, and its history of net losses. Opportunities are vast, given the growing market for obesity and NASH treatments, potential partnerships, and the possibility of expanding into other metabolic diseases. Threats include intense competition from larger pharmaceutical companies, potential clinical trial failures, and regulatory hurdles. The article suggests that while pemvidutide's potential could drive stock value, investors should consider the inherent risks associated with clinical-stage biotech companies.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/general/altimmune-s-swot-analysis-pemvidutide-potential-drives-stock-outlook/ar-AA1xLijY ]